Androstan-3-one,17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5a,17b)- cas no:434-07-1
Synonyms: 5a-Androstan-3-one,17b-hydroxy-2-(hydroxymethylene)-17-methyl- (6CI,8CI);17-Beta-Hydroxy-2-hydroxymethylene-17-alpha-methyl-3-androstanone;17a-Methyl-2-hydroxymethylene-17-hydroxy-5a-androstan-3-one;17b-Hydroxy-2-(hydroxymethylene)-17a-methyl-5a-androstan-3-one;2-Hydroxymethylene-17a-methyl-17b-hydroxy-3-androstanone;2-Hydroxymethylene-17a-methylandrostan-17b-ol-3-one;2-Hydroxymethylene-17b-hydroxy-17a-methyl-5a-androstan-3-one;Adroyd;Anadrol;Anapolan 50;Anapolon;Anasteron;Anasteronal;Anasterone;Becorel;C.I. 406;HMD;NSC-26198;Nastenon;Oxymethenolone;Oxymetholone;Pardroyd;Plenastril;Protanabol;Roboral;Synasteron;Synasteron 50;
NameAndrostan-3-one,17-hydroxy-2-(hydroxymethylene)-17-methyl-, (5a,17b)-
CAS434-07-1
Synonyms5a-Androstan-3-one,17b-hydroxy-2-(hydroxymethylene)-17-methyl- (6CI,8CI);17-Beta-Hydroxy-2-hydroxymethylene-17-alpha-methyl-3-androstanone;17a-Methyl-2-hydroxymethylene-17-hydroxy-5a-androstan-3-one;17b-Hydroxy-2-(hydroxymethylene)-17a-methyl-5a-androstan-3-one;2-Hydroxymethylene-17a-methyl-17b-hydroxy-3-androstanone;2-Hydroxymethylene-17a-methylandrostan-17b-ol-3-one;2-Hydroxymethylene-17b-hydroxy-17a-methyl-5a-androstan-3-one;Adroyd;Anadrol;Anapolan 50;Anapolon;Anasteron;Anasteronal;Anasterone;Becorel;C.I. 406;HMD;NSC-26198;Nastenon;Oxymethenolone;Oxymetholone;Pardroyd;Plenastril;Protanabol;Roboral;Synasteron;Synasteron 50;
EINECS(EC#)207-098-6
Molecular FormulaC21H32O3
Molecular Weight332.48
Appearancewhite crystalline powder
alpha34 o
refractive index38 ° (C=1, CHCl3)
storage temp2-8°C
Hazard T: Toxic;
Risk R40
Safety Confirmed human carcinogen producing liver tumors. Human systemic effects by ingestion: impaired liver function. An experimental teratogen. Experimental reproductive effects. When heated to decomposition it emits acrid smoke and irritating fumes. See also TESTOSTERONE.
SYMPTOMS: Symptoms of exposure to Oxymetholone may include cholestatic jaundice, hepatocellular neoplasms and peliosis hepatitis. Prepubertal exposure may cause phallic enlargement and increased frequency of erection. Postpubertal exposure may cause inhibition of testicular function, testicular atrophy, oligospermia, impotence, chronic priapism, epididymitis, bladder irritability, clitoral enlargement, menstrual irregularities, increased or decreased libido, excitation, insomnia, nausea, vomiting, diarrhea, leukemia, gynecomastia, deepening of the voice in women, hirsutism and male-pattern baldness in women, acne, edema, retention of serum electrolytes and decreased glucose tolerance. It may also cause higher risk of developing liver cell tumors. Other symptoms include abnormal liver function tests, salt and water retention and masculinization, particularly of the female fetus.
